{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T11:40:30Z","timestamp":1784288430444,"version":"3.55.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Although the management of nausea and vomiting induced by cancer treatments has evolved, several questions remain unanswered.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>New antiemetics have been developed these last decades with therapeutic indications to be defined according to the anticancer regimen and partly as a consequence of the assessment of individual patient risk factors. Guidelines still seem to have a low level of knowledge and compliance, with a role for scientific societies in term of dissemination and education. A number of persistent issues relating to emesis still need improvement in prevention and management. Nausea remains a subjective semantic whose evaluation should possibly benefit from educational programs. The risk classification of anticancer drugs must be regularly updated, requiring regular literature reviews and the integration of data from clinical trials relating to emerging anticancer drugs. Recent data, particularly in the context of emerging drugs, highlight the importance to consider emesis\u2019 impact beyond the 5-day period, with a potential adaptation of antiemetic prophylaxis, including the mode of administration of oral drugs.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Guidelines update is presented with literature answers to the current issues in order to improve quality of patient's management in the context of emesis related to anticancer therapies.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cco.0000000000001114","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T15:07:43Z","timestamp":1737990463000},"page":"158-162","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["Chemotherapy-induced nausea and vomiting: can we do better?"],"prefix":"10.1097","volume":"37","author":[{"given":"Florian","family":"Scott\u00e9","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"R1-20250207","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1056\/NEJMra1515442","article-title":"Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting","volume":"374","author":"Navari","year":"2016","journal-title":"N Engl J Med"},{"issue":"(Suppl 1)","key":"R2-20250207","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00520-018-4131-3","article-title":"CINV: still troubling patients after all these years","volume":"26","author":"Aapro","year":"2018","journal-title":"Support Care Cancer"},{"key":"R3-20250207","doi-asserted-by":"crossref","first-page":"102195","DOI":"10.1016\/j.esmoop.2023.102195","article-title":"2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting","volume":"9","author":"Herrstedt","year":"2024","journal-title":"ESMO Open"},{"key":"R4-20250207","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00520-023-08221-4","article-title":"2023 updated MASCC\/ESMO consensus recommendations: prevention of nausea and vomiting following high-emetic-risk antineoplastic agents","volume":"32","author":"Herrstedt","year":"2023","journal-title":"Support Care Cancer"},{"key":"R5-20250207","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00520-023-08222-3","article-title":"2023 updated MASCC\/ESMO Consensus recommendations: prevention of nausea and vomiting following moderately emetic risk antineoplastic agents","volume":"32","author":"Scott\u00e9","year":"2023","journal-title":"Support Care Cancer"},{"issue":"(Suppl 5)","key":"R6-20250207","doi-asserted-by":"crossref","first-page":"v119","DOI":"10.1093\/annonc\/mdw270","article-title":"2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients","volume":"27","author":"Roila","year":"2016","journal-title":"Ann Oncol"},{"key":"R7-20250207","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00520-023-08223-2","article-title":"2023 updated MASCC\/ESMO consensus recommendations: controlling nausea and vomiting with chemotherapy of low or minimal emetic potential","volume":"32","author":"Olver","year":"2023","journal-title":"Support Care Cancer"},{"key":"R8-20250207","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1093\/annonc\/mds021","article-title":"The effect of guideline-consistent antiemetic therapy on chemotherapy-induced nausea and vomiting (CINV): the Pan European Emesis Registry (PEER)","volume":"23","author":"Aapro","year":"2012","journal-title":"Ann Oncol"},{"key":"R9-20250207","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1200\/JOP.2012.000816","article-title":"Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting in US community practice: INSPIRE Study","volume":"10","author":"Gilmore","year":"2013","journal-title":"J Onc Pract"},{"key":"R10-20250207","doi-asserted-by":"crossref","first-page":"e1073","DOI":"10.1002\/onco.13716","article-title":"Practice patterns for prevention of chemotherapy-induced nausea and vomiting and antiemetic guideline adherence based on real-world prescribing data","volume":"26","author":"Aapro","year":"2021","journal-title":"Oncologist"},{"key":"R11-20250207","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1056\/NEJMp0911494","article-title":"The missing voice of patients in drug-safety reporting","volume":"362","author":"Basch","year":"2010","journal-title":"N Engl J Med"},{"key":"R12-20250207","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1093\/annonc\/mdx100","article-title":"The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting","volume":"28","author":"Dranitsaris","year":"2017","journal-title":"Ann Oncol"},{"key":"R13-20250207","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1007\/s00520-004-0718-y","article-title":"Evaluation of new antiemetic agents and definition of antineoplastic agent emetogenicity--an update","volume":"13","author":"Grunberg","year":"2005","journal-title":"Support Care Cancer"},{"key":"R14-20250207","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s00520-024-08543-x","article-title":"MASCC 2023 Patient-Centered Antiemetic Guidelines and Education Statements: an evidence-based and consensus resource for patients","volume":"32","author":"Affronti","year":"2024","journal-title":"Support Care Cancer"},{"key":"R15-20250207","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00520-023-08220-5","article-title":"Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents-updated MASCC\/ESMO consensus recommendation","volume":"32","author":"Jordan","year":"2023","journal-title":"Support Care Cancer"},{"key":"R16-20250207","first-page":"e975","article-title":"Optimal supportive care with selinexor improves outcomes in patients with relapsed\/refractory multiple myeloma. Clinical lymphoma, myeloma and leukemia","volume":"21","author":"Chari","year":"2021"},{"key":"R17-20250207","first-page":"309601","article-title":"Prevention of nausea and vomiting in patients undergoing oral anticancer therapies for solid tumors","author":"Costa","year":"2015","journal-title":"BioMed Res Int"},{"key":"R18-20250207","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/j.jpainsymman.2013.06.012","article-title":"Evaluation of risk factors predicting chemotherapy-related nausea and vomiting: results from a European prospective observational study","volume":"47","author":"Molassiotis","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"R19-20250207","doi-asserted-by":"crossref","first-page":"1549","DOI":"10.1007\/s00520-010-0982-y","article-title":"Risk factors at pretreatment predicting treatment-induced nausea and vomiting in Australian cancer patients: a prospective, longitudinal, observational study","volume":"19","author":"Pirri","year":"2011","journal-title":"Support Care Cancer"},{"key":"R20-20250207","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1093\/annonc\/mdx120","article-title":"Identifying predictive factors of chemotherapy-induced nausea and vomiting (CINV): a novel approach","volume":"28","author":"Scott\u00e9","year":"2017","journal-title":"Ann Oncol"},{"key":"R22-20250207","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1186\/s12885-020-6707-9","article-title":"Netupitant\/palonosetron (NEPA) and dexamethasone for prevention of emesis in breast cancer patients receiving adjuvant anthracycline plus cyclophosphamide: a multicycle, phase II study","volume":"20","author":"Caputo","year":"2020","journal-title":"BMC Cancer"},{"key":"R23-20250207","doi-asserted-by":"crossref","first-page":"3217","DOI":"10.1007\/s12325-023-02537-7","article-title":"Real-world treatment outcomes, healthcare resource use, and costs associated with antiemetics among cancer patients on cisplatin-based chemotherapy","volume":"40","author":"Navari","year":"2023","journal-title":"Adv Ther"},{"issue":"(Supp 2)","key":"R24-20250207","doi-asserted-by":"crossref","first-page":"S1093","DOI":"10.1016\/j.annonc.2023.09.860","article-title":"2078P Evaluation of chemotherapy-induced nausea and vomiting beyond the delayed phase: results of a survey of healthcare providers in Japan","volume":"34","author":"Scott\u00e9","year":"2023","journal-title":"Ann Oncol"},{"key":"R25-20250207","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s00520-023-07978-y","article-title":"Prevalence and predictors of long-delayed (>120\u200ah) chemotherapy-induced nausea and vomiting (CINV)-a systematic review and individual patient data meta-analysis","volume":"31","author":"Chow","year":"2023","journal-title":"Support Care Cancer"},{"key":"R26-20250207","doi-asserted-by":"crossref","first-page":"100553","DOI":"10.1016\/j.esmoop.2022.100553","article-title":"Optimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancer","volume":"7","author":"Rugo","year":"2022","journal-title":"ESMO Open"},{"key":"R27-20250207","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41523-022-00467-1","article-title":"Safety analyses from the phase 3 ASCENT trial of sacituzumab govitecan in metastatic triple-negative breast cancer","volume":"8","author":"Rugo","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"R28-20250207","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1007\/s12094-024-03383-x","article-title":"Safety profile of trastuzumab deruxtecan in advanced breast cancer: expert opinion on adverse event management","volume":"26","author":"Ciruelos","year":"2024","journal-title":"Clin Transl Oncol"},{"key":"R29-20250207","doi-asserted-by":"crossref","first-page":"102113","DOI":"10.1016\/j.eclinm.2023.102113","article-title":"Toxicity profile of antibody-drug conjugates in breast cancer: practical considerations","volume":"62","author":"D\u2019Arienzo","year":"2023","journal-title":"EClinicalMedicine"}],"container-title":["Current Opinion in Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001114","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T13:01:08Z","timestamp":1738933268000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCO.0000000000001114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/cco.0000000000001114","relation":{},"ISSN":["1040-8746","1531-703X"],"issn-type":[{"value":"1040-8746","type":"print"},{"value":"1531-703X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]}}}